Non-corticosteroid drug-induced metabolic bone disease;Ostéopathies médicamenteuses (hors cortisone)

Presse Medicale

Volumn 35, Issue 10 II, 2006, Pages 1579-1583

  Briot, Karine ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIVITAMIN K; AROMATASE INHIBITOR; BUMETANIDE; CHLORPROMAZINE; CYCLOSPORIN A; EXEMESTANE; GABAPENTIN; GONADORELIN AGONIST; HALOPERIDOL; HEPARIN; LAMOTRIGINE; LETROZOLE; LEVOTHYROXINE; LITHIUM; METHOTREXATE; NEUROLEPTIC AGENT; OLANZAPINE; PIOGLITAZONE; PROTEINASE INHIBITOR; RISPERIDONE; ROSIGLITAZONE; TACROLIMUS; TAMOXIFEN; THYROID HORMONE; THYROTROPIN; UNINDEXED DRUG; VALPROIC ACID;

BONE DENSITOMETRY; BONE DENSITY; BONE MASS; CORTICOSTEROID THERAPY; DRUG INDUCED DISEASE; FRAGILITY FRACTURE; HUMAN; METABOLIC BONE DISEASE; REVIEW; SECONDARY OSTEOPOROSIS;

EID: 33749644174     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0755-4982(06)74854-0     Document Type: Review

References (44)

1. Orcel P. Prise en charge de l'ostéoporose cortisonique. Presse Med. 2006; 35: 1571-7.
2. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF et al. Results of the ATAC (Arimidex, Tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005; 365: 60-2.
3. Eastell R, Adams J. Results of the Arimidex (anastrozole A), (tamoxifen T), alone or in combination (C) (ATAC) trial: effects on Bone Mineral Density (BMD) and bone turnover (ATAC trialist group. Annals Oncol. 2002; 13 (suppl 5): 113PD, 32.
4. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003; 349: 1793-802.
5. Coombes RC, Hall E, Gibson EJ, Paridaens R, Jassem J, Deloziert T et al. A randomized trial of exemestane after two years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004; 350: 1081-92.
6. Lonning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol. 2005; 23: 5126-37.
7. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005; 352: 154-64.
8. Lopez AM, Pena MA, Hernandez R, Val F, Martin B, Riancho JA. Fracture risk in patients with prostate cancer on androgen deprivation therapy. Osteoporos Int. 2005; 16: 707-11.
9. Daniell HW. Osteoporosis due to androgen deprivation therapy in men with prostate cancer. Urology. 2001; 58: 101-7.
10. Kiratli BJ, Srinivas S, Perkash I, Terris MK. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology. 2001; 57: 127-32.
11. Surrey ES, Hornstein MD. Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. Obstet Gynecol. 2002; 99: 709-19.
12. Fernandez H, Lucas C, Hedon B, Meyer JL, Mayenga JM, Roux C. One year comparison between two add-back therapies in patients treated with a GnRH agonist for symptomatic endometriosis: a randomized double-blind trial. Hum Reprod. 2004; 19: 1465-71.
13. Vestergaard P. Epilepsy, osteoporosis and fracture risk - a metaanalysis. Acta Neurol Scand. 2005, 112: 277-86.
14. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE et al. TM. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med. 1995; 332: 767-73.
15. Espallargues M, Sampietro-Colom L, Estrada MD, Sola M, del Rio L, Setoain J et al. Identifying bone-mass-related risk factors for fracture to guide bone densitometry measurements: a systematic review of the literature. Osteoporos Int. 2001; 12: 811-22.
16. Ensrud KE, Walczak TS, Blackwell T, Ensrud ER, Bowman PJ, Stone KL. Antiepileptic drug use increases rates of bone loss in older women: a prospective study. Neurology. 2004; 62: 2051-7.
17. Petty SJ, Paton LM, O'Brien T, Makovey J, Erbas B, Sambrook P, Berkovic SF, Wark JD. Effect of antiepileptic medication on bone mineral measures. Neurology. 2005; 65: 1358-63.
18. Farhat G, Yamout B, Mikati MA, Demirjian S, Sawaya R, El-Hajj Fuleihan G. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology. 2002; 58: 1348-1353.
19. Fitzpatrick LA. Pathophysiology of bone loss in patients receiving anticonvulsant therapy. Epilepsy Behav. 2004; 5 suppl 2: S3-15.
20. Barbour LA, Kick SD, Steiner JF, LoVerde ME, Heddleston LN, Lear JI et al. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol. 1994; 170: 862-70.
21. Monreal M, Vinas L, Moreal L, Lavin S, Lafoz E, Angles AN. Heparin-related osteoporosis in rats. A comparative study between unfractioned heparin and a low-molecular weight-heparin. Haemostasis. 1990; 20: 204-7.
22. Fuller K, Chambers TJ, Gallagher AC. Heparin augments osteoclast resorption-stimulating activity in serum. J Cell Physiol. 1991; 147: 208-14.
23. Hodges SJ, Akesson K, Vergnaud P, Obrant K, Delmas PD. Circulating levels of vitamins K1 and K2 decreased in elderly women with hip fracture. J Bone Miner Res. 1993; 8: 1241-5.
24. Jamal SA, Browner WS, Bauer DC, Cummings SR. Warfarin use and risk for osteoporosis in elderly women. Ann Intern Med. 1998; 128: 829-32.
25. Caraballo PJ, Heit JA, Atkinson EJ, Silverstein ND, O'Fallon WM, Castro MR et al. Long-term use of oral anticoagulants and the risk of fracture. Arch Intern Med. 1999; 159: 1750-6.
26. Caraballo PJ, Gabriel SE, Castro MR, Atkinson EJ, Melton EJ 3rd. Changes in bone density after exposure to oral anticoagulants: a meta-analysis. Osteoporos Int. 1999; 9; 441-8.
27. Szulc P, Arlot M, Chapuy MC, Duboeuf F, Meunier PJ, Delmas PD. Serum undercarboxylated osteocalcin correlates with hip bone mineral density in elderly women. J Bone Miner Res. 1994; 9: 1591-5.
28. Meaney AM, Smith S, Howes OD, O'Brien M, Murray RM, O'Keane V. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry. 2004; 184: 503-8.
29. O'Keane V, Meaney AM. Antipsychotics drugs: a new risk factor for osteoporosis in young women with schizophrenia? J Clin Psychopharmacol. 2005; 25: 26-31.
30. Bilici M, Cakirbay H, Guler M, Tosun M, Ulgen M, Tan U. Classical and atypical neuroleptics, and bone mineral density, in patients with shizophrenia. Int J Neurosci. 2002; 112: 817-28.
31. Faber J, Galloe AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol. 1994; 130: 350-6.
32. Greenspan SL, Greenspan FS. The effect of thyroid hormone on skeletal integrity. Ann Intern Med. 1999; 130: 750-8.
33. Mak TW, Shek CC, Chow CC, Wing YK, Lee S. Effects of lithium therapy on bone mineral metabolism: a two-year prospective longitudinal study. J Clin Endocrinol Metab. 1998; 83: 3857-9.
34. Cohen O, Rais T, Lepkifker E, Vered I. Lithium carbonate therapy is not a risk factor for osteoporosis. Horm Metab Res. 1998; 30: 594-7.
35. Minaur NJ, Kounali D, Vedi S, Compston JE, Beresford JN, Bhalla AK. Methotrexate in the treatment of rheumatoid arthritis II. In vivo effects on bone mineral density. Rheumatology. 2002; 41: 741-9.
36. Buckley EM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol. 1997; 24: 1489-94.
37. May KP, West SG, McDermott MT, Huffer WE. The effect of low-dose methotrexate on bone metabolism and histomorphometry in rats. Arthritis Rheum. 1994; 37: 201-6.
38. Bowman AR, Sass DA, Dissanayake IR, Ma YF, Liang H, Yuan Z et al. The role of testosterone in cyclosporin-induced osteopenie. J Bone Miner Res. 1997; 12: 607-15.
39. Monegal A, Navasa M, Guanabens N, Peris P, Pons F, Martinez de Osaba MJ et al. Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine A. Calcif Tissue Int. 2001; 68: 83-6.
40. Amiel C, Ostertag A, Slama L, Baudoin C, N'Guyen T, Lajeunie E et al. BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res. 2004; 19: 402-9.
41. Rejnmark L, Vestergaard P, Heickendorff L, Andreasen F, Mosekilde L. Loop diuretics increase bone turnover and decrease BMD in osteopenic postmenopausal women: results from a randomized controlled study with bumetanide. J Bone Miner Res. 2006; 21: 163-70.
42. Rejnmark L, Vestergaard P, Mosekilde L. Fracture risk in patients treated with loop diuretics. J Inter Med. 2006; 259: 117-24.
43. Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology. 2005; 146: 1226-35.
44. Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold KR et al. Thiazolidinedione (TZD) use and bone loss in older diabetic adults. J Clin Endocrinol Metab. 2006; In press.